HEART: Pilot Randomized Controlled Trial
Recruiting now · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Thoracic Aortic Aneurysm
In brief
The purpose of this study is to determine whether spironolactone reduces aortic stiffness, measured by carotid-femoral pulse wave velocity (cfPWV), compared with placebo, in patients with degenerative thoracic aortic aneurysms.
Key facts
- Study ID
- NCT07483177
- Run by
- Mayo Clinic
- People needed
- 50
- Starts
- 2026-05-25
- Expected to finish
- 2028-05-01
- Last updated by the study team
- 2026-06-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adults ≥ 18 years old with dTAA of the aortic root and/or ascending aorta exceeding the upper limit of normal for age, sex, and body surface area (≥ 4.0 cm as an example of a common threshold; but age, sex and body size-specific thresholds have been established for the aortic root24 and ascending aorta25);
- no antihypertensive use or stable antihypertensive regimen ≥ 4 weeks;
- eGFR ≥ 50 mL/min/1.73 m²;
- serum potassium ≤ 5.1 mmol/L;
- ability to provide informed consent.
You may not qualify if…
- Heritable aortopathies (Marfan, Loeys-Dietz, vascular Ehlers-Danlos, Turner syndromes; familial TAA, genetically-proven TAA);
- bicuspid aortic valve;
- inflammatory aortitis,
- prior aortic surgery, endovascular repair, or acute aortic syndrome;
- permanent atrial fibrillation/flutter;
- major peripheral artery disease affecting the carotids, iliacs and/or external femoral arteries precluding cfPWV measurement;
- current use of spironolactone, eplerenone or finererone;
- pregnancy or lactation.
Where it is running
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.